1800 244 735

Helpline (02) 9874 9777

Melatonin alterations in Huntington's disease help explain trouble with sleep

Many people with Huntington’s disease have problems sleeping. Sleep-wake cycles are controlled in part by melatonin, a hormone that makes you drowsy at bedtime. Scientists in London measured melatonin levels in HD patients, gene carriers, and unaffected individuals and found changes in the levels and timing of melatonin release. This could help to explain the sleep disruptions that occur in HD.

Sleep can be elusive

If you’ve ever been in bed with your mind racing, wishing for sleep, you know that slipping into dreamland is far less simple than it seems. In fact it requires a lot of complex coordination by different parts of the brain to get your body in tune with the darkening world, leaving you drowsy enough to fall asleep and restful enough to stay that way till morning.

We know that people with Huntington’s disease sleep poorly: nearly 80% of Huntington’s disease sufferers experience sleep disturbances. These can include an increase in the length of time it takes to fall asleep, changes in what the brain is doing during sleep, and decreases in the amount of truly restful sleep. It’s not well understood why these disturbances occur in HD, but a new study highlights changes in levels of melatonin, a chemical that regulates sleep and wakefulness in relation to the rising and setting of the sun.

Brain control of sleep

Our predisposition for nighttime sleep and daytime activity is just one of many circadian rhythms, a term that refers to anything that changes within our bodies on a 24-hour cycle, and can be synchronized with what’s happening in our environment. Lots of human behaviors are rhythmic or change predictably over the course of a day. Not only sleep and alertness, but also digestion, body temperature, and the immune system change depending on what time it is. We’ve talked about sleep and circadian rhythms in Huntington’s disease before..

These rhythms are overseen by a brain region called the suprachiasmatic nucleus, or SCN. The SCN acts as the brain’s timekeeper, coordinating the body’s activities over the 24-hour day. Neurons in the SCN are perfectly situated to communicate with cells from the eyes that describe how much light there is in the environment. With this information, the SCN can send out a message to other brain and body areas telling them what they need to do to keep their cycles running smoothly.

Because of the resulting circadian rhythms, levels of all kinds of substances made by the body can fluctuate normally with the amount of light outside, and melatonin is an important one. Melatonin is a hormone, a chemical messenger that circulates in the blood. It is produced by an organ deep in the center of the brain called the pineal gland. As the sun begins to go down, the SCN senses the change in light and sends a message to the pineal gland to start secreting melatonin. Melatonin helps to regulate sleep cycles by causing drowsiness and lowering the body’s temperature a little in preparation for sleeping through the night. Melatonin levels are high throughout the night, but as the sun comes back up, they drop, corresponding with increased wakefulness.

Are melatonin levels altered in HD?

Since Huntington’s disease patients have problems regulating the normal sleeping/waking cycle, a group of researchers in the UK led by Prof Tom Warner wanted to ask whether the rise and fall of melatonin levels in HD patients is abnormal compared to unaffected individuals. Previous studies had measured patients’ melatonin at a single time point, early in the morning, but Warner’s group wanted to monitor melatonin levels throughout the 24-hour cycle to get a better sense of how the rhythm of melatonin production is affected in HD.

They recruited 13 patients with moderate to advanced HD, and 15 people who do not have the HD gene. They also included 14 people who carry the HD gene, but had not yet shown disease symptoms. Each person involved in the study spent a day and night in a private room, under supervision by clinicians. They could walk around and do what they liked during the day, but they weren’t allowed to nap, and the lights were out between 10 pm and 6 am. The researchers inserted an IV line so that they could collect a small amount of blood every hour, even in the middle of the night, with minimal interruption of the volunteers’ sleep.

Melatonin in HD and gene carriers: lower levels and improper timing

Using a sensitive type of chemical analysis, the researchers determined the amount of melatonin in each person’s blood, then compared the three groups with one another using a variety of statistical methods.

They found that the HD patients had much lower levels of melatonin in their blood than those without HD – around 85% lower on average. Presymptomatic carriers of the HD gene also had slightly lower melatonin levels than normal.

Another finding was that HD patients and gene carriers showed more variation in the time of day that their melatonin levels began to rise. Most of the volunteers without HD had a surge of melatonin around bedtime, while HD-affected individuals’ melatonin levels rose at different times – some in the afternoon, some in the middle of the night.

An explanation for disrupted sleep in HD?

By consistently monitoring blood levels of melatonin for a full 24 hours in Huntington’s disease patients, presymptomatic HD carriers, and unaffected control participants, this study showed that melatonin levels are indeed altered in HD, a finding which may help to explain why patients experience disrupted sleep.

The researchers go on to suggest that a low or poorly-timed surge of melatonin from the pineal gland could mean that there’s something wrong with the timekeeper neurons in the SCN. Several different types of Huntington’s disease mice have shown problems in sleep and other cyclic behaviors controlled by the SCN. Abnormalities in signalling chemicals produced by the SCN have been found in HD brains, both human and mouse.

Back in 2011, we reported on a study in which melatonin treatment improved behavior and survival in Huntington’s disease mice. It’s not yet clear whether we can link that finding with the new discovery of decreased melatonin levels in HD patients. But sleep disruption can be a major source of stress and can worsen the symptoms of many diseases. Improving sleep through melatonin therapy, could be a positive change for the body and brain. However, it’s not yet clear whether melatonin is effective in HD to improve sleep, let alone as a means of slowing down the progression of the disease.

A case for clinical trials of melatonin

There hasn’t been a clinical trial of melatonin as a therapy for Huntington’s disease patients with sleep disturbances, but this study provides good evidence of HD-related changes in melatonin levels, and suggests that a clinical trial might be warranted. Melatonin is already an approved supplement that many people buy over-the-counter or get on prescription, to adjust their sleep patterns. Some patients appear more responsive than others to melatonin and other sleep aids; perhaps this could be explained by the variable timing of melatonin production that this study found in HD patients.

Finally, these results don’t provide any explanation for why changes in melatonin occur in HD. We can speculate that the SCN or its communication with the pineal gland may be disrupted, but the reasons for that are unclear. It’s also fairly clear that changes in melatonin are only one of several things that can cause sleep disruption in Huntington’s disease, and we’re definitely not saying that every HD patient should take melatonin. However, these results make a solid case for a clinical trial, and importantly, the study provides one explanation for why it’s so tough for many HD patients to catch some much-needed zzzs.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Plenary Meeting 2020

Published date: 8 January, 2021

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn ... Read more

Uncovering the dark side of DNA repair to design HD treatments

Published date: 22 December, 2020

A gene known as ‘MSH3’, which encodes a protein involved in fixing and maintaining our DNA, has become a hot topic in Huntington’s research since being implicated as a key driver of the disease by multiple genetic studies. In a recent publication, a team of scientists from the National University of Ireland, Galway, have provided ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 2

Published date: 1 November, 2020

The second day of the HSG conference was another busy day of presentations from HD researchers and clinicians. The day kicked off with a talk from Vaccinex who gave us an overview of their work on the SIGNAL clinical trial. Unfortunately, pepinemab, the medicine tested in this trial, did not influence HD symptoms and the ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 1

Published date: 30 October, 2020

The Huntington Study Group (HSG) is a clinical research network focused exclusively on HD. Yesterday the HSG annual conference began with a schedule jam-packed with virtual talks from researchers, clinicians and different companies who are all working towards finding new medicines for HD. The day encompassed many interesting presentations which covered a lot of the ... Read more

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Published date: 22 October, 2020

While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation to branaplam. An existing drug…for huntingtin lowering? The pharmaceutical company Novartis has announced that the U.S. Food and Drug Administration ... Read more

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Published date: 23 September, 2020

The SIGNAL clinical trial was designed to test a drug called pepinemab in people with early Huntington’s disease. The key results of that trial were recently announced, and unfortunately, pepinemab did not slow or improve HD symptoms as hoped. What was the SIGNAL trial, and who participated? The SIGNAL trial was launched in 2015 by ... Read more

Welcome to our new website!

Please bear with us while we iron out the last minute wrinkles! If you have any feedback about our new site, please fill out the form below.